Avidity Partners Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Avidity Partners Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,482,200	Closed	-$91.7M	–	116
2022 Q3	$91.7M	Sell	1,482,200 -374,700	-20%	-$26.2M	1.87%	20
2022 Q2	$148M	Buy	1,856,900 +725,500	+64%	+$68.7M	3.4%	10
2022 Q1	$119M	Buy	1,131,400 +119,400	+12%	+$11.6M	2.48%	14
2021 Q4	$109M	Buy	1,012,000 +186,000	+23%	+$20.3M	2.31%	14
2021 Q3	$90.5M	Buy	826,000 +258,000	+45%	+$26.8M	2%	13
2021 Q2	$53.2M	Sell	568,000 -13,000	-2%	-$1.2M	1.44%	26
2021 Q1	$53.5M	Sell	581,000 -588,300	-50%	-$49.6M	1.48%	23
2020 Q4	$85.5M	Buy	1,169,300 +239,100	+26%	+$17.8M	2.78%	9
2020 Q3	$72.3M	Buy	930,200 +394,000	+73%	+$27.1M	3.35%	8
2020 Q2	$29.8M	Buy	536,200 +203,200	+61%	+$8.69M	1.91%	18
2020 Q1	$9.86M	Buy	333,000 +183,000	+122%	+$6.19M	1.36%	29
2019 Q4	$5.43M	Buy	+150,000	New	+$4.6M	3.42%	12

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Avidity Partners Management's HZNP Position: Q4 2022 in Review

Avidity Partners Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022, closing a stake of 1,482,200 shares — an estimated $91.7M sold.

Avidity Partners Management first reported a position in HZNP in Q4 2019 and held it in 12 quarters. The position peaked at $148M in Q2 2022. 613 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

Avidity Partners Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Avidity Partners Management sold 1,482,200 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $91.7M.
Avidity Partners Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2019 and held it in 12 quarters.
Avidity Partners Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $148M in Q2 2022.
613 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on Avidity Partners Management's 13F filing for Q4 2022, filed 14 Feb 2023.